A practical guide to the handling and administration of talimogene laherparepvec in Europe

OncoTargets and Therapy

Volumn 10, Issue , 2017, Pages 3867-3880

  Harrington, Kevin J ^a   Michielin, Olivier ^b   Malvehy, Josep ^c,d   Pezzani Grüter, Isabella ^e   Grove, Lorna ^f   Frauchiger, Anna Lisa ^g   Dummer, Reinhard ^g  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e AMGEN INC   (United States)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Herpes simplex virus; Intralesional injection; Melanoma; Oncolytic immunotherapy; Practical considerations; Talimogene laherparepvec

Indexed keywords

IPILIMUMAB; PEMBROLIZUMAB; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TALIMOGENE LAHERPAREPVEC; VIRUS DNA;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CELLULITIS; CHILL; DNA MODIFICATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; EUROPE; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; FREEZE THAWING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH CARE DELIVERY; HERPES SIMPLEX; HOSPITAL HYGIENE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INJECTION SITE PAIN; INTERDISCIPLINARY COLLABORATION; LIVER CELL CARCINOMA; LIVER METASTASIS; MEDICAL EDUCATION; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRACTICE GUIDELINE; PREGNANT WOMAN; PROTECTIVE EQUIPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REIMBURSEMENT; REVIEW; SEROCONVERSION; SHARPS DISPOSAL; SHELF LIFE; SOLID MALIGNANT NEOPLASM; STORAGE TEMPERATURE; TREATMENT DURATION; TREATMENT RESPONSE; VASCULITIS; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS SHEDDING; VITILIGO;

EID: 85026825390     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S133699     Document Type: Review

References (46)

1. Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy. 2015;7(6):611–619.
2. Sloot S, Rashid OM, Zager JS. Intralesional therapy for metastatic melanoma. Expert Opin Pharmacother. 2014;15(18):2629–2639.
3. Tronnier M, Mitteldorf C. Treating advanced melanoma: current insights and opportunities. Cancer Manag Res. 2014;6:349–356.
4. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus obser­vation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I–III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004;100(8):1692–1698.
5. Thompson JF, Agarwala SS, Smithers BM, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22(7):2135–2142.
6. Weide B, Eigentler TK, Pflugfelder A, et al. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol Res. 2014;2(7):668–678.
7. von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer. 1988;61(6):1071–1074.
8. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res. 1996;6(3):247–255.
9. Heinzerling L, Burg G, Dummer R, et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther. 2005;16(1):35–48.
10. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet. 2001;357(9255):525–526.
11. Watanabe D, Goshima F, Mori I, Tamada Y, Matsumoto Y, Nishiyama Y. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci. 2008;50(3):185–196.
12. Andtbacka RHI, Curti BD, Kaufman H, et al. Final data from CALM: a phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immu­notherapy in patients with advanced melanoma. J Clin Oncol. 2015;33 Suppl:abstract 9030.
13. Urosevic M, Fujii K, Calmels B, et al. Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas. J Clin Invest. 2007;117(10):2834–2846.
14. Heinzerling L, Kunzi V, Oberholzer PA, Kundig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts anti­tumor immune responses in vivo and targets interferon-resistant tumor cells. Blood. 2005;106(7):2287–2294.
15. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther. 2011;19(6):1008–1016.
16. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559–567.
17. Pol JG, Rességuier J, Lichty BD. Oncolytic viruses: a step into cancer immunotherapy. Virus Adapt Treat. 2012;4:1–21.
18. Harrington KJ, Puzanov I, Hecht JR, et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015;15(12):1389–1403.
19. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laher­parepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788.
20. NICE National Institute for Health and Care Excellence. Talimogene laherparepvec for treating unresectable metastatic melanoma. Technol­ogy appraisal [TA410]. 2016. Available from: https://www.nice.org.uk/guidance/ta410. Accessed October 3, 2016.
21. IMLYGIC® (talimogene laherparepvec) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; 2015.
22. IMLYGIC® (talimogene laherparepvec) [summary of product charac­teristics]. Breda: Amgen Europe B.V.; 2016.
23. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303.
24. Fukuhara H, Todo T. Oncolytic herpes simplex virus type 1 and host immune responses. Curr Cancer Drug Targets. 2007;7(2):149–155.
25. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol. 2002;3(1):17–26.
26. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene. 2003;22(20):3188–3192.
27. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010;16(15):4005–4015.
28. Harrington KJ, Andtbacka FHI, Collichio F, et al. Disease characteristics, treatment outcomes and safety with talimogene laherparepvec vs GM-CSF in patients with stage IIIB/C and IVM1a melanoma in OPTiM. Poster presented at: 11th European Association of Dermato Oncology (EADO) Congress and 8th World Meeting of Interdisciplinary Mela­noma/Skin Cancer Centers, Marseille, France; October 28–31, 2015.
29. Harrington KJ, Andtbacka RH, Collichio F, et al. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther. 2016;9:7081–7093.
30. Andtbacka RH, Ross M, Puzanov I, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol. 2016;23(13):4169–4177.
31. Puzanov I, Milhem MM, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB–IV melanoma. J Clin Oncol. 2016;34(22):2619–2626.
32. Chesney J, Collichio F, Andtbacka RH, et al. Interim efficacy and safety of a randomized (1:1) open-label phase 2 study of talimogene laherparepvec and ipilimumab vs ipilimumab alone in unresected, stage IIIB–IV melanoma. Ann Oncol. 2016;27 Suppl 6:379–400.
33. Long GV, Dummer R, Ribas A, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec and pembrolizumab for unresected stage IIIB–IV melanoma. Poster presented at: American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA; June 3–7, 2016.
34. IMLYGIC® (talimogene laherparepvec) [prescribing information]. Zug: Amgen Switzerland AG; 2016.
35. Abdullah HA. Talimogene laherparepvec: advanced therapy medicinical product (ATMP) – a distinct risk management plan. Poster presented at: Develop Innovate Advance (DIA) meeting, Philadelphia, PA, USA; June 26–30, 2016.
36. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737–6747.
37. IMLYGIC™ (talimogene laherparepvec) [safety data sheet]. Thousand Oaks, CA: Amgen Inc.; 2016.
38. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–5771.
39. Amatruda T, Mehnert J, Walker J, et al. Interim analysis (IA) of a phase 2 multicenter single arm clinical trial to evaluate biodistribu­tion and shedding of talimogene laherparepvec (T-VEC) in patients (pts) with unresected Stages IIIB–IV melanoma. Poster presented at: Society for Melanoma Research (SMR) Congress, Boston, MA, USA; November 6–9, 2016.
40. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420.
41. Seymour L, Bogaerts J, Perrone A, et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152.
42. Choi JH, Ahn MJ, Rhim HC, et al. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer Res Treat. 2005;37(5):290–293.
43. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
44. Harrington KJ, Andtbacka RHI, Collichio F, et al. Benefit and risk analysis from the phase III OPTiM trial of talimogene laherparepvec (T-VEC) vs granulocyte-stimulating factor (GM-CSF) in patients with stage IIIB–IV melanoma. Poster presented at: 11th European Associa­tion of Dermato Oncology (EADO) Congress and 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, Marseille, France; October 28–31, 2015.
45. World Health Organization. Laboratory Biosafety Manual. 3rd ed. 2004. Available from: http://www.who.int/csr/resources/publications/biosafety/en/Biosafety7.pdf. Accessed October 3, 2016.
46. Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: talimo­gene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53.